OptimizeRx
OPRX
64 hedge funds and large institutions have $109M invested in OptimizeRx in 2019 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 25 increasing their positions, 15 reducing their positions, and 6 closing their positions.
133% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 6
67% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 15
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
14% more funds holding
Funds holding: 56 → 64 (+8)
5.76% more ownership
Funds ownership: 47.58% → 53.34% (+5.8%)
4% more capital invested
Capital invested by funds: $106M → $109M (+$3.84M)
3% less call options, than puts
Call options by funds: $1.24M | Put options by funds: $1.27M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GIPM
G2 Investment Partners Management
New York
|
+$4.94M |
| 2 |
BlackRock
New York
|
+$2.6M |
| 3 |
CCM
Cadence Capital Management
Boston,
Massachusetts
|
+$2.46M |
| 4 |
TAM
THB Asset Management
Norwalk,
Connecticut
|
+$2.28M |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$2.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
-$1.53M |
| 2 |
MHP
Manatuck Hill Partners
Westport,
Connecticut
|
-$1.38M |
| 3 |
Russell Investments Group
London,
United Kingdom
|
-$868K |
| 4 |
Renaissance Technologies
New York
|
-$520K |
| 5 |
1CM
1492 Capital Management
Milwaukee,
Wisconsin
|
-$464K |
OPRX Hedge Fund Activity: Q3 2019 in Review
64 of the 4,574 institutional investors tracked by Wall St. Rank reported a position in OptimizeRx (OPRX) for Q3 2019, worth a combined $109M — up 3.6% from $106M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new OPRX positions and 6 closed out — a net gain of 8 holders — while 25 added to existing stakes and 15 trimmed.
The largest buyer was G2 Investment Partners Management, adding an estimated $4.94M. The largest seller was Marshall Wace, exiting entirely with an estimated $1.53M sold.
- 64 institutional investors held OptimizeRx (OPRX) as of Q3 2019, up from 56 in Q2 2019.
- Funds reported $109M of OptimizeRx stock for Q3 2019, up 3.6% quarter-over-quarter.
- 14 funds opened new OptimizeRx positions in Q3 2019 and 6 closed out, a net change of +8 holders.
- The largest OptimizeRx buyer in Q3 2019 was G2 Investment Partners Management, an estimated $4.94M added.
- The largest OptimizeRx seller in Q3 2019 was Marshall Wace, an estimated $1.53M sold.
Based on aggregated 13F filings for Q3 2019.